[Skip to Content]
[Skip to Content Landing]

Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsA Systematic Review and Meta-analysis

Educational Objective
To learn the incidence and types of fatal toxic effects associated with immune checkpoint inhibitors
1 Credit CME
Key Points

Question  What are the spectrum, timing, and incidence of fatal toxic effects associated with immune checkpoint inhibitors?

Findings  A broad range of regimen-specific toxic effects caused fatalities in 0.3% to 1.3% of treated patients; fatal toxic effects tended to occur very early in treatment (median of 40 and 14.5 days for monotherapy and combination immunotherapy, respectively).

Meaning  Fatal toxic effects from immune checkpoint inhibitors are rare but have diverse causes; awareness is needed among clinicians across disciplines given the increase in use of these agents.

Abstract

Importance  Immune checkpoint inhibitors (ICIs) are now a mainstay of cancer treatment. Although rare, fulminant and fatal toxic effects may complicate these otherwise transformative therapies; characterizing these events requires integration of global data.

Objective  To determine the spectrum, timing, and clinical features of fatal ICI-associated toxic effects.

Design, Setting, and Participants  We retrospectively queried a World Health Organization (WHO) pharmacovigilance database (Vigilyze) comprising more than 16 000 000 adverse drug reactions, and records from 7 academic centers. We performed a meta-analysis of published trials of anti–programmed death-1/ligand-1 (PD-1/PD-L1) and anti–cytotoxic T lymphocyte antigen-4 (CTLA-4) to evaluate their incidence using data from large academic medical centers, global WHO pharmacovigilance data, and all published ICI clinical trials of patients with cancer treated with ICIs internationally.

Exposures  Anti–CTLA-4 (ipilimumab or tremelimumab), anti–PD-1 (nivolumab, pembrolizumab), or anti–PD-L1 (atezolizumab, avelumab, durvalumab).

Main Outcomes and Measures  Timing, spectrum, outcomes, and incidence of ICI-associated toxic effects.

Results  Internationally, 613 fatal ICI toxic events were reported from 2009 through January 2018 in Vigilyze. The spectrum differed widely between regimens: in a total of 193 anti–CTLA-4 deaths, most were usually from colitis (135 [70%]), whereas anti–PD-1/PD-L1–related fatalities were often from pneumonitis (333 [35%]), hepatitis (115 [22%]), and neurotoxic effects (50 [15%]). Combination PD-1/CTLA-4 deaths were frequently from colitis (32 [37%]) and myocarditis (22 [25%]). Fatal toxic effects typically occurred early after therapy initiation for combination therapy, anti–PD-1, and ipilimumab monotherapy (median 14.5, 40, and 40 days, respectively). Myocarditis had the highest fatality rate (52 [39.7%] of 131 reported cases), whereas endocrine events and colitis had only 2% to 5% reported fatalities; 10% to 17% of other organ-system toxic effects reported had fatal outcomes. Retrospective review of 3545 patients treated with ICIs from 7 academic centers revealed 0.6% fatality rates; cardiac and neurologic events were especially prominent (43%). Median time from symptom onset to death was 32 days. A meta-analysis of 112 trials involving 19 217 patients showed toxicity-related fatality rates of 0.36% (anti–PD-1), 0.38% (anti–PD-L1), 1.08% (anti–CTLA-4), and 1.23% (PD-1/PD-L1 plus CTLA-4).

Conclusions and Relevance  In the largest evaluation of fatal ICI-associated toxic effects published to date to our knowledge, we observed early onset of death with varied causes and frequencies depending on therapeutic regimen. Clinicians across disciplines should be aware of these uncommon lethal complications.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Douglas B. Johnson, MD, Vanderbilt University Medical Center, 2220 Pierce Ave, 777 Preston Research Bldg, Nashville, TN 37232 (douglas.b.johnson@vumc.org).

Accepted for Publication: June 6, 2018.

Correction: This article was corrected on October 11, 2018, to fix the fatality rate percentage for adrenal depicted in Figure 1C.

Published Online: September 13, 2018. doi:10.1001/jamaoncol.2018.3923

Author Contributions: Dr Johnson had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Wang, Salem, Chandra, Das, Balko, Chism, Long, Hassel, Moslehi, Johnson.

Acquisition, analysis, or interpretation of data: Wang, Salem, Cohen, Menzer, Ye, Zhao, Das, Beckermann, Ha, Rathmell, Ancell, Balko, Bowman, Davis, Horn, Long, Carlino, Lebrun-Vignes, Eroglu, Hassel, Menzies, Sosman, Sullivan, Johnson.

Drafting of the manuscript: Wang, Chandra, Ye, Balko, Long, Menzies, Sosman, Sullivan, Moslehi, Johnson.

Critical revision of the manuscript for important intellectual content: Wang, Salem, Cohen, Menzer, Zhao, Das, Beckermann, Ha, Rathmell, Ancell, Balko, Bowman, Davis, Chism, Horn, Long, Carlino, Lebrun-Vignes, Eroglu, Hassel, Menzies, Sosman, Sullivan, Moslehi, Johnson.

Statistical analysis: Wang, Ye, Zhao, Long, Johnson.

Obtained funding: Rathmell, Johnson.

Administrative, technical, or material support: Salem, Ha, Rathmell, Bowman, Chism, Long, Carlino, Hassel, Menzies, Sullivan, Johnson.

Study supervision: Salem, Menzer, Rathmell, Lebrun-Vignes, Hassel, Moslehi, Johnson.

Conflict of Interest Disclosures: Dr Johnson serves on advisory boards for Array Biopharma, Bristol Myers Squibb, Incyte, Merck, Novartis, and Navigate BP, and receives research funding from Bristol Myers Squibb and Incyte. Dr Rathmell receives research funding from Incyte. Dr Menzies serves on advisory boards for BMS, MSD Merck, Novartis, Roche and Pierre-Fabre. Dr Long serves on advisory boards and steering committees for Amgen, Array Biopharma, Bristol Myers Squibb, Incyte, Merck, Novartis, Pierre-Fabre and Roche. Dr Sosman serves on Advisory Boards for Bristol Myers Squibb, Incyte, Genentech, and Curis. No other disclosures are reported.

Funding/Support: This study was supported by The Cancer ITMO of the French National Alliance for Life and Health Sciences (AVIESAN): “Plan Cancer 2014-2019” (Drs Salem and Lebrun-Vignes) by NIH/NCI K23 CA204726 (Dr Johnson), NIH K24 CA172355 (Dr Rathmell), the James C. Bradford Jr Melanoma Fund (Dr Johnson), and the Melanoma Research Foundation (Dr Johnson).

Role of the Funder/Sponsor: The National Alliance for Life and Health Sciences, National Institutes of Health, the James C. Bradford Jr Melanoma Fund, and the Melanoma Research Foundation had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: The supplied data from Vigilyze come from a variety of sources. The likelihood of a causal relationship is not the same in all reports. The information does not represent the opinion of the World Health Organization.

References
1.
Wolchok  JD, Chiarion-Sileni  V, Gonzalez  R,  et al.  Overall survival with combined nivolumab and ipilimumab in advanced melanoma.  N Engl J Med. 2017;377(14):1345-1356. doi:10.1056/NEJMoa1709684PubMedGoogle ScholarCrossref
2.
Hammers  HJ, Plimack  ER, Infante  JR,  et al.  Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 Study.  J Clin Oncol. 2017;35(34):3851-3858. doi:10.1200/JCO.2016.72.1985PubMedGoogle ScholarCrossref
3.
Hellmann  MD, Rizvi  NA, Goldman  JW,  et al.  Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.  Lancet Oncol. 2017;18(1):31-41. doi:10.1016/S1470-2045(16)30624-6PubMedGoogle ScholarCrossref
4.
Antonia  SJ, López-Martin  JA, Bendell  J,  et al.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.  Lancet Oncol. 2016;17(7):883-895. doi:10.1016/S1470-2045(16)30098-5PubMedGoogle ScholarCrossref
5.
Motzer  RJ, Tannir  NM, McDermott  DF,  et al; CheckMate 214 Investigators.  Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.  N Engl J Med. 2018;378(14):1277-1290. doi:10.1056/NEJMoa1712126PubMedGoogle ScholarCrossref
6.
Postow  MA, Sidlow  R, Hellmann  MD.  Immune-Related adverse events associated with immune checkpoint blockade.  N Engl J Med. 2018;378(2):158-168. doi:10.1056/NEJMra1703481PubMedGoogle ScholarCrossref
7.
Hassel  JC, Heinzerling  L, Aberle  J,  et al.  Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.  Cancer Treat Rev. 2017;57:36-49. doi:10.1016/j.ctrv.2017.05.003PubMedGoogle ScholarCrossref
8.
Shoushtari  AN, Friedman  CF, Navid-Azarbaijani  P,  et al.  Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma.  JAMA Oncol. 2018;4(1):98-101.PubMedGoogle ScholarCrossref
9.
Johnson  DB, Balko  JM, Compton  ML,  et al.  Fulminant myocarditis with combination immune checkpoint blockade.  N Engl J Med. 2016;375(18):1749-1755. doi:10.1056/NEJMoa1609214PubMedGoogle ScholarCrossref
10.
Naidoo  J, Wang  X, Woo  KM,  et al.  Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy.  J Clin Oncol. 2017;35(7):709-717. doi:10.1200/JCO.2016.68.2005PubMedGoogle ScholarCrossref
11.
Koelzer  VH, Rothschild  SI, Zihler  D,  et al.  Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study.  J Immunother Cancer. 2016;4:13. doi:10.1186/s40425-016-0117-1PubMedGoogle ScholarCrossref
12.
Wang  DY, Ye  F, Zhao  S, Johnson  DB.  Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis.  Oncoimmunology. 2017;6(10):e1344805. doi:10.1080/2162402X.2017.1344805PubMedGoogle ScholarCrossref
13.
Fellner  A, Makranz  C, Lotem  M,  et al.  Neurologic complications of immune checkpoint inhibitors.  J Neurooncol. 2018;137(3):601-609. doi:10.1007/s11060-018-2752-5PubMedGoogle ScholarCrossref
14.
Moslehi  JJ, Salem  JE, Sosman  JA, Lebrun-Vignes  B, Johnson  DB.  Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.  Lancet. 2018;391(10124):933. doi:10.1016/S0140-6736(18)30533-6PubMedGoogle ScholarCrossref
15.
Beer  TM, Kwon  ED, Drake  CG,  et al.  Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer.  J Clin Oncol. 2017;35(1):40-47. doi:10.1200/JCO.2016.69.1584PubMedGoogle ScholarCrossref
16.
Lindquist  M.  VigiBase, the WHO Global ICSR Database System: basic facts.  Drug Inf J. 2008;42(5):409-419. doi:10.1177/009286150804200501Google ScholarCrossref
17.
Moher  D, Liberati  A, Tetzlaff  J, Altman  DG; PRISMA Group.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.  PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097PubMedGoogle ScholarCrossref
18.
Heberle  H, Meirelles  GV, da Silva  FR, Telles  GP, Minghim  R.  InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams.  BMC Bioinformatics. 2015;16:169. doi:10.1186/s12859-015-0611-3PubMedGoogle ScholarCrossref
19.
Pignon  JP, Tribodet  H, Scagliotti  GV,  et al; LACE Collaborative Group.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.  J Clin Oncol. 2008;26(21):3552-3559. doi:10.1200/JCO.2007.13.9030PubMedGoogle ScholarCrossref
20.
Gooley  TA, Chien  JW, Pergam  SA,  et al.  Reduced mortality after allogeneic hematopoietic-cell transplantation.  N Engl J Med. 2010;363(22):2091-2101. doi:10.1056/NEJMoa1004383PubMedGoogle ScholarCrossref
21.
Long  GV, Weber  JS, Infante  JR,  et al.  Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib.  J Clin Oncol. 2016;34(8):871-878. doi:10.1200/JCO.2015.62.9345PubMedGoogle ScholarCrossref
22.
Soria  JC, Ohe  Y, Vansteenkiste  J,  et al; FLAURA Investigators.  Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer.  N Engl J Med. 2018;378(2):113-125. doi:10.1056/NEJMoa1713137PubMedGoogle ScholarCrossref
23.
Cameron  JL, Riall  TS, Coleman  J, Belcher  KA.  One thousand consecutive pancreaticoduodenectomies.  Ann Surg. 2006;244(1):10-15. doi:10.1097/01.sla.0000217673.04165.eaPubMedGoogle ScholarCrossref
24.
Bailey  SH, Bull  DA, Harpole  DH,  et al.  Outcomes after esophagectomy: a ten-year prospective cohort.  Ann Thorac Surg. 2003;75(1):217-222. doi:10.1016/S0003-4975(02)04368-0PubMedGoogle ScholarCrossref
25.
Weber  J, Mandala  M, Del Vecchio  M,  et al; CheckMate 238 Collaborators.  Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.  N Engl J Med. 2017;377(19):1824-1835. doi:10.1056/NEJMoa1709030PubMedGoogle ScholarCrossref
26.
Antonia  SJ, Villegas  A, Daniel  D,  et al; PACIFIC Investigators.  Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer.  N Engl J Med. 2017;377(20):1919-1929. doi:10.1056/NEJMoa1709937PubMedGoogle ScholarCrossref
27.
Betof  AS, Nipp  RD, Giobbie-Hurder  A,  et al.  Impact of age on outcomes with immunotherapy for patients with melanoma.  Oncologist. 2017;22(8):963-971. doi:10.1634/theoncologist.2016-0450PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close